547 related articles for article (PubMed ID: 21948291)
1. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
[TBL] [Abstract][Full Text] [Related]
2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of midregional pro-A-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years.
Karakas M; Jaensch A; Breitling LP; Brenner H; Koenig W; Rothenbacher D
Clin Chem; 2014 Nov; 60(11):1441-9. PubMed ID: 25139456
[TBL] [Abstract][Full Text] [Related]
4. Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP.
Chenevier-Gobeaux C; Guerin S; André S; Ray P; Cynober L; Gestin S; Pourriat JL; Claessens YE
Clin Chem; 2010 Nov; 56(11):1708-17. PubMed ID: 20813917
[TBL] [Abstract][Full Text] [Related]
5. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study.
McKie PM; Cataliotti A; Sangaralingham SJ; Ichiki T; Cannone V; Bailey KR; Redfield MM; Rodeheffer RJ; Burnett JC
Mayo Clin Proc; 2011 Dec; 86(12):1154-60. PubMed ID: 22134933
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
[TBL] [Abstract][Full Text] [Related]
8. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
Tofte N; Theilade S; Winther SA; Birkelund S; Goetze JP; Hansen TW; Rossing P
Diabetes Care; 2021 Feb; 44(2):595-603. PubMed ID: 33323477
[TBL] [Abstract][Full Text] [Related]
10. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus.
Letzner J; Berger F; Schwabe S; Benzing J; Morgenthaler NG; Bucher HU; Bührer C; Arlettaz R; Wellmann S
Neonatology; 2012; 101(2):116-24. PubMed ID: 21952518
[TBL] [Abstract][Full Text] [Related]
11. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP.
Gegenhuber A; Struck J; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
Clin Chem; 2006 May; 52(5):827-31. PubMed ID: 16543387
[TBL] [Abstract][Full Text] [Related]
12. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
[TBL] [Abstract][Full Text] [Related]
14. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.
Tan ESJ; Chan SP; Liew OW; Chong JPC; Gerard Leong KT; Daniel Yeo PS; Ong HY; Jaufeerally F; Sim D; Ling LH; Lam CSP; Richards AM
JACC Heart Fail; 2024 Mar; 12(3):461-474. PubMed ID: 37897459
[TBL] [Abstract][Full Text] [Related]
15. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
[TBL] [Abstract][Full Text] [Related]
16. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
17. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
[TBL] [Abstract][Full Text] [Related]
18. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Hansen PM; Kamstrup PR; Faber J; Køber L; Schou M
Biomarkers; 2020 May; 25(3):248-259. PubMed ID: 32126847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
